Targeted KRAS TCR NK cell therapy(Immuxell Biotech)

N/A

Report date: 2024/07/11 11:35:41

Base Information

Drug NameTargeted KRAS TCR NK cell therapy(Immuxell Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulatorsNatural killer cell replacements

TargetsGTPase KRas

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShanghai Immuxell Biotech Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Immuxell Biotech Ltd

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A